T HERE ARE NOW at least nine naturally occurring pharmacologically active amines in mammals that are formed by decarboxylation of their amino acid precursors. The reactions are listed below, together with relative rates of formation of the amines: 3, 4-Dihydroxyphenylalanine 3000 1 -2 (DOPA) at nerve endings; is bound or stored there in inactive form inaccessible to degradative enzymes; is released and metabolized gradually in quiescence and massively during nerve activity; stimulates the effector; and then is destroyed rapidly. A large literature has been devoted to the physiological functions of these amines, and current work is being done. Many investigators believe that most, if not all, of them exert their effects on the cardiovascular and nervous system primarily by interaction with specialized chemical processes at synaptic junctions where nerve impulses are transmitted by release and diffusion of neurohumoral transmitters, such as acetylcholine and norepinephrine.
A neurohumoral transmitter is thought of as a substance that is synthesized and found From the Psychopharmacology Research Unit, VA Hospital, Sepulveda, and the Medical Center, University of California, Los Angeles, California.
Supported by the National Association for Mental Health, the U.S. Public Health Service, the American Heart Association, the American Cancer Society, the National Science Foundation, the Army Chemical Center, and the Los Angeles County Heart Association.
Circulation Research, Volume IX, May 1961 721 It is probable that most of these amines are "modulators" rather than true transmitters. Insofar as the central nervous system is concerned, acetylcholine fulfills most, but not all, of the requirements just listed for a transmitter. Serotonin and norepinephrine also fulfill many of these requirements. We know that dopamine, norepinephrine, and serotonin are present, synthesized, stored, released, exert effects, and are destroyed afterward. Their stores probably are in specialized particles or vesicles.
A given substance or drug can affect nerve transmission through a neurohormone by: (a) altering the synthesis of the neuro-*Recently we have demonstrated that threo-dlphenylserine-2-C'*, after being hydroxylated to labeled p-hydroxyphenylserine, can give rise to labeled octopamine when incubated with mouse mast-cell-tumor homogenate. Evidence also was obtained that it was directly decarboxylated to labeled pheiiylethanolamine. Inhibition of blood-pressure response to intravenous D0PA by sodium 5-( 3' -hydroxycinnamoyl) s'alicylate.
hormone at the presynaptic nerve endings; (b) altering its uptake, storage, and release; (c) altering its metabolism; (d) altering its diffusion or transmission across the synaptic cleft; (e) altering its action at the receptor; or (f) mimicking its action at the receptor.
Almost nothing is known about such matters in the heart and blood-vessel receptors. However, the elucidation of the existence, binding, release, synthesis, and metabolism of such substances as norepinephrine, doparnine, etc. has had a profound effect on cardiovascular physiology. This paper will be limited to a consideration of one of the processes by which drugs may affect nerve transmission, namely, the alteration of function by changing the synthesis of endogenous amines known to exert cardiovascular, neurological, and psychological effects.
Because there are several steps in the synthesis of amines from precursor ammo acids, it is theoretically possible to inhibit their synthesis in several ways. By suppressing synthesis, amine stores available for transmission or modulation of nerve impulses peripherally and centrally may be reduced, and this may be reflected in altered function.
Similar changes may be produced by modification of some of the other five modes of action at nerve endings. For example, reserpine, by releasing norepinephrine and serotonin, causes tranquilization, impaired adrenergic transmission, and hypotension. Thus the use of drugs that affect synthesis, in combination with those that affect one or more of the other five modes of action, could be of great interest and value.
More than 10 years ago, the thought occured to us that, of all the steps in the biosynthesis of norepinephrine, inhibition of D0PA decarboxylase offered the greatest promise of blocking the formation of norepinephrine. Accordingly, we began a study of the characteristics of this enzyme system, including its kinetics, cofactors, temperature and pH optima, and substrates.
In 1951, Schott reported that the coenzyme, pyridoxal-5-phosphate, reacted through its aldehyde moiety with the amino group of the substrate D0PA, inactivating the coenzyme and blocking decarboxylation. The norepinephrine reaction product is a tetrahydroisoquinoline, formed by ring-closure of the side chain to the vieta hydroxyl group on the ring. This was the first demonstration of inhibition of an enzyme system by chemical interaction of substrate and coenzyme. Schott showed that for rapid reaction there must be a free meta hydroxyl group on the ring and an unsubstituted amine in the side chain. Thus, o-hydroxyphenylalanine does not react well, nor does epinephrine, which is a secondary amine in contrast M'ith norepinephrine, a primary amine.
One interesting outgrowth of the investigations stimulated by Schott's studies 19 -20 has been the recent discovery by Gonnard 21 " 20 that hydrazones formed by condensing substances such as benzoic acid hydrazide with pyridoxal-5-phosphate no longer inhibit the deearboxylation, but protect the coenzyme from interaction with the substrate by blocking the reactive aldehyde group. Such hydrazones act as true eoenzymes and permit the reaction to go to completion, unlike the natural process that plateaus before completion. Recently, Schott and Masuoka 27 ' 28 studied the methylation of norepinephrine to epinephrine by the S-adenosylmethionine-magnesium-transmethylase system in vitro and in vivo, using beta-C 14 -norepinephrine of high specific activity, synthesized in this laboratory. 29 The isotopic dilution method necessary in this work did not separate epinephrine from contaminating radioactive norepinephrine, an observation also made by Udenfriend and Wyngaarden. 30 Accordingly, a method was devised to remove the norepinephrine by virtue of its reactivity with pyridoxal-5phosphate. Thus Sehott and Masuoka obtained the first direct evidence that norepinephrine is converted to epinephrine without alteration of the molecule, thereby confirming and extending the original observation of Keller, Boissonnas, and du Vigneaud 31 who used radioactive methionine as methyl donor.
In 1950, Martin et al. 32 reported the first systematic study of structural analogues of DOPA as possible competitive inhibitors of DOPA decarboxylase in vitro. They found good inhibition by several analogues including Circulation Research. Volume IX, May 1961 p-hydroxyphenylpyruvic acid, and, because these compounds also depressed blood pressure acutely in dogs, they postulated a correlation between the depressor effect and the in vitro enzyme inhibition. Unfortunately the low yields of CO2, the relatively high concentrations of inhibitors used, the relative inactivity of their compounds as reported by Hartman et al., 33 and the unlikelihood that inhibitors of DOPA decarboxylase in vivo will have an immediate depressor effect, have made their data questionable. Nevertheless their report was provocative and stimulated further work.
Early in 1951, Furst et al. 34 reported that p-hydroxycinnamie acid OH 0 II CH = CH -C -OH was a powerful competitive inhibitor of phenylalanine and tyrosine utilization by a number of micro-organisms. It was suggested to Hartman that he try it as a decarboxylase relatively specific for DOPA decarboxylase, since no inhibition was seen with the bacterial decarboxylases of tyrosine, histidine, and glutamie acid, nor with mammalian tyrosinase and succinic acid dehydrogenase, nor in the respiration of surviving rat-liver slices.
Sourkes, in 1954, 36 tested a group of phenylalanine analogues prepared by Stein, Bronner, and Pfister 37 during a program of developing amino acid antagonists by introducing a methyl group on the alpha-carbon. One compound of their series, 38 dl-a-methj\glutamic acid, was found by Eoberts 39 to be a good competitive inhibitor of bacterial glutamie acid decarboxylase, which forms gamma-aminobutyric acid, subsequently found by him and others to exist specifically in the brain and to exert neurophysiological effects. 40 Umbreit 41 has reviewed the metabolic
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antagonistic effects of amino acids, in which the alpha-hydrogen atom has been replaced by a methyl group.
Of the 22 analogues examined, Sourkes found that a-methyldopa (oc-methyl-DOPA) and a-methyl-m-tyrosine were good inhibitors at 1 to 5 X 10-* M and 5 X 10" 3 to 5 X 10~3 M respectively, when preincubated with enzyme before adding substrate. Subsequently we found 33 that, when added simultaneously M'ith enzyme and substrate, a-methyldopa inhibition of DOPA deearboxylase was only 35 per cent at Kh 3 M (0.1 E.M.) In the hope of finding structures that will inhibit the enzyme in vivo for longer periods than observed thus far, some interesting structural analogues of serotonin have been examined by Yuwiler, Geller, and Eiduson for their action on DOPA and 5-hydroxytryptophan decarboxylase. 42 45 and of E. W. Page and Reed 46 ' 47 that DOPA is decarboxylated rapidly in vivo and that the product, dopamine, is excreted in the urine. Intravenously injected DOPA causes a slow-rising, sustained pressor response lasting several minutes, owing to dopamine formation ( fig. 1 ). The pressor response occurs normally after removal of the kidneys, the gastrointestinal tract, or in the properly prepared, completely eviscerated cat ( fig. 2 ).
Page and Reed believed the pressor effect of DOPA might not be due to decarboxylation alone because catechol and acetaldehyde also produced pressor responses. Holtz and Credner 48 also thought that DOPA itself might be the cause' of the pressor response and showed that other polyphenols, such as catechol and hydroquinone, are indeed pressor but, unlike DOPA, the response is immediate. The changes in blood pressure and heart rate were shown by Pogrund and Clark to be due to the' dopamine formed from DOPA and ( -)-norepinephrine from Ww-eo-cZW^-dihydroxyphenylserine and ( + )norepinephrine from en/Wiro-<^-3,4-dihydroxyphenylserine, 49 In extending our in vitro studies of DOPA decarboxylase inhibitors to in vivo systems, a quantitative assay was developed. We were unsuccessful in quantitating the technique of Bing and Zucker, 50 ' r>1 modified by Beyer, •' 2 of injecting DOPA into the ischemic kidneys in vivo and observing a rise in blood Circulation Research, Volume IX, May 19B1 pressure when the renal circulation subsequently is re-established. The assay finally settled upon was difficult and laborious and an art. Only one or two compounds could be assayed per day because the preparation failed or did not give reproducible responses. The assay consisted of recording the pressor responses of cocainized, pithed cats or rats to DOPA as affected by an unknown inhibitor, compared in the same animal as a control, with a known, standard inhibitor taken as unity. The value of the assay lies in the fact that in the name animal a control response can be quantitatively compared with that from a compound being assayed, and, also in the same animal, the duration of the effect can be compared with that of the standard, thus giving a measure of the rate of its metabolism (see fig. 1 ).
About 80 compounds were examined in this manner, using pithed cats when supplies of the compounds were plentiful, and rats when meager. The pithed-rat preparation is more difficult because of the greater sensitivity to drugs and improper artificial respiration. The results were expressed as moles of unknown that depressed the DOPA pressor response 50 per cent of normal, compared wth moles of standard that also de- pressed it 50 per cent, as illustrated in figure 7A and B.
The results on about 30 active and 50 related but inactive compounds have been tabulated elsewhere. 53 It is interesting, although uncertain of interpretation 55 ' 57 that, if a "Lineweaver-Burk analysis'' is made in vivo, the inhibitors appear to be competitive, injections of large amounts of D0PA causing displacement of inhibitor and more rapid recovery of responses to the original small dose of DOPA. This was done by measuring responses to small increasing doses of DOPA and theu repeating these measurements in the presence of a given dose of inhibitor and plotting the reciprocals of response units against reciprocals of DOPA doses in the absence and presence of inhibitor. Approximately converging straight lines resulted, although not so clearly as in similar in vitro experiments ( fig. 8) .
These studies showed no strict quantitative parallelism between inhibition in vitro and in vivo, but those substances that were inactive n vitro almost always were inactive in vivo. The one or two exceptions found could be explained by metabolic conversion to active structures, for example, by esterase action on acetylated compounds.
One of the most active compounds was 5-(3-hydroxycinnamoyl) salicylic acid, OH COOH OH CH = CH -C which is a meia-hydroxychalcone. In vitro it was less active than its dihydroxy analogue. Presumably the body may O-methylate the latter too rapidly.
All the compounds tested were catabolized in 30 to 60 minutes, and DOPA responses again were normal. The meta-chalcone inhibited DOPA pressor responses in doses of 5 to 10 mg./Kg., and the 50 per cent inhibitory doses were sometimes as low as 1 to 2 mg./Kg. Several species were tested and all were affected. The acute toxicity LD 50 is 380 mg./Kg. after intraperitoneal injection in mice.
Because of the rapid detoxication, further work on the physiology and pharmacodynamics was not planned until compounds of longer duration were developed. Present activities are directed at organic syntheses.
Nevertheless, an attempt was made to test the possibility that the inhibitors might block the biosynthesis of norepinephrine and epinephrine in vivo. 58 Prolonged insulin coma was induced in rats to deplete the adrenal medullary catecholamines. The rate of "repletion" or resynthesis of epinephrine and norepinephrine was then measured.
In one experiment, after recovery from 8 hours insulin coma, animals were divided into several groups: some served as untreated controls, others as insulin-coma controls, and still other groups received different doses of one of the inhibitors, eaffeic acid, intraperitoneally every 4 hours for 48 hours. The adrenal glands were then analyzed. Significant inhibition was seen, especially at the 50 mg./Kg. dose level ( fig. 9 ).
Unfortunately, this work, which required the use of more than 800 animals, was done with eaffeic and chlorogenic acids, relatively weak inhibitors, and before more potent compounds were found. It also was done before we knew that the compounds are completely detoxified within 30 to 60 minutes.
No effects of the inhibitors have been seen so far on the fatigability of the nictitatingmembrane response to constant electrical stimulation of the postganglionic superior sympathetic nerve in the cat, which one might expect if the stores of norepinephrine at the nerve endings were released and prevented from replenishment by synthesis from precursors.
Drell, in our laboratory, obtained preliminary evidence 59 that one inhibitor, 5-(3-hydroxycinnamoyl)salicylic acid, by inhibiting DOPA decarboxylase in surviving slices of beef adrenal gland, causes a marked decrease in radioactivity in catecholamines formed from C 14 -tryosine and an increase in the labeled eatechol acids, suggesting a piling up of DOPA.
In 1957, Dengler and Keichel, 60 in Holtz's Laboratory, showed that a-methyldopa, the inhibitor studied first by Sourkes, inhibits the pressor response to DOPA and DOPS and correlated this with decreased decarboxylase activity measured in the removed kidneys. Westermann et al., 01 in the same laboratory, confirmed and extended this to 5-hydroxytryptophan decarboxylation in guinea pigs, and in addition showed that the a-methyldopa prevented the bronchoconstrictor effect of 5-hydroxytryptophan caused by its decarboxylation to serotonin. In addition, they showed that the excitatory effect of 5hydroxytryptophan in iproniazid-treated animals under hexobarbital (Evipan) is inhibited by a-methyldopa.
Smith 62 ' 63 showed that large single doses of a-methyldopa inhibited brain and intestinal 5-hydroxytryptophan decarboxylase in mice and endogenous brain serotonin was decreased. Repeated large doses decreased brain and gut serotonin about 100 per cent.
Sourkes and Murphy 8460 confirmed these findings, and showed that a-methyl-3-hydroxy. 4-methoxyphenylalanine, a-methyl-3-hydroxyphenylalanine, and a-methyl-3-niethoxyptienylalanine also prevented dopamine formation from DOPA in the brain. Udenfriend 70 Fellman, 17 Bosengren, 72 and others.
Sjoerdsma et al. 73 ' 77 reported that a-methyldopa and its analogue, a-methyl-m-tyrosine, had interesting effects in patients with diseases believed in part to be associated with aberrations in amine metabolism, including essential hypertension, pheochromocytoma, and carcinoid. These effects were in part explained by inhibition of the formation of catecholamines and serotonin by blocking their decarboxylases. Animal studies by Hess, Ozaki, and Udenfriend 78 and by Porter et al. 70 have confirmed the findings of Smith and of Sourkes that levels of the amines can be reduced in the brain, heart, and other organs. Smith, Sjoerdsma et al., and Porter et al. all noticed that in addition to depleting amines, presumably in part by inhibiting their formation, the a-methyl-substituted inhibitors also interfered with the uptake-binding-release mechanisms, especially for norepinephrine in contrast with serotonin. This led Smith to suggest that such compounds had an action similar to that of reserpine, and it is of interest that Dengler (personal communication) found that a-methyldopa markedly impaired the active uptake of IF-norepinephrine by surviving brain slices, whereas Schanberg and Giarman 80 reported no such interference in the active uptake of 5-hydroxytryptophan by brain slices. Day and Green 81 observed a much greater inhibition of the active uptake of histaniine by mast cells in tissue culture than on inhibition of histidine decarboxylate by a-methyldopa. 16 
